Terms: = Endocrine gland cancer AND MUTYH, MYH, 4595, ENSG00000132781, hMYH, MGC4416, MYHbeta AND Treatment
12 results:
1. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
2. Outcomes of ATA Low-Risk Pediatric Thyroid cancer Patients Not Treated With Radioactive Iodine Therapy.
Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
[TBL] [Abstract] [Full Text] [Related]
3. DNA Repair Pathway in Ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
4. Forty-eight-year-old female mutyh carrier presenting with five concurrent primary cancers.
Arroyave A; Nodit L; Clegg D; Russ A
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1455. PubMed ID: 34173730
[TBL] [Abstract] [Full Text] [Related]
5. The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid cancer Patients on Tyrosine Kinase Inhibitor Therapy.
Tomoda C; Sugino K; Kitagawa W; Nagahama M; Ito K
ORL J Otorhinolaryngol Relat Spec; 2021; 83(5):347-353. PubMed ID: 33735904
[TBL] [Abstract] [Full Text] [Related]
6. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or Ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
7. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden.
Cao Y; Ma Y; Yu J; Sun Y; Sun T; Shao Y; Li J; Shen L; Lu M
Cancer Commun (Lond); 2020 Dec; 40(12):746-751. PubMed ID: 33230973
[TBL] [Abstract] [Full Text] [Related]
8. A case report of a patient with first phenotype of papillary thyroid carcinoma and heterochronous multiprimary tumor harboring germline mutyh Arg19*/Gly286Glu mutations.
Wang M; Zhu F; Luo N; Han T; Wang M
Oral Oncol; 2021 Jan; 112():104987. PubMed ID: 32888815
[TBL] [Abstract] [Full Text] [Related]
9. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
[TBL] [Abstract] [Full Text] [Related]
10. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.
Khrunin AV; Khokhrin DV; Moisseev AA; Gorbunova VA; Limborska SA
Pharmacogenomics; 2014 Feb; 15(3):329-37. PubMed ID: 24533712
[TBL] [Abstract] [Full Text] [Related]
12. Dry eye syndrome in aromatase inhibitor users.
Turaka K; Nottage JM; Hammersmith KM; Nagra PK; Rapuano CJ
Clin Exp Ophthalmol; 2013 Apr; 41(3):239-43. PubMed ID: 22957932
[TBL] [Abstract] [Full Text] [Related]
